A 48-year-old woman undergoes mastectomy and sentinel lymph node biopsy for a 3 cm invasive lobular carcinoma of the left breast. Intraoperative sentinel node examination (frozen section) shows metastatic carcinoma in 1 of 2 sentinel nodes. The surgeon proceeds to axillary lymph node dissection (ALND). Postoperatively, the final histopathology of the ALND specimen shows no additional metastatic nodes in the remaining 12 nodes. What is the most appropriate investigation to assess for distant metastases before initiating adjuvant therapy?

Explanation

## Investigation Choice: Distant Staging in Node-Positive Breast Cancer ### Clinical Context The patient has node-positive breast cancer (pN1: 1/2 sentinel nodes involved, 0/12 additional nodes = pN1a) requiring accurate distant staging (M-staging) before adjuvant systemic therapy planning. ### Why CT Chest, Abdomen, and Pelvis is Correct **Key Point:** CT chest, abdomen, and pelvis (CAP) is the standard investigation for M-staging in node-positive breast cancer. It detects visceral, hepatic, and pelvic metastases with high sensitivity and specificity [cite:NCCN Breast Cancer Guidelines 2023]. **High-Yield:** CT CAP is recommended for all patients with: - Node-positive disease (pN1, pN2, pN3) - Locally advanced breast cancer (T3, T4) - Symptoms suggestive of metastatic disease **Clinical Pearl:** CT CAP has ~85–90% sensitivity for detecting metastatic disease in the lungs, liver, and peritoneal cavity. It is more sensitive than chest X-ray alone and does not expose the patient to the radiation burden of PET-CT in asymptomatic node-positive disease. ### Comparison of Distant Staging Investigations | Investigation | Sensitivity | Specificity | Indication | Radiation Burden | Cost | |---|---|---|---|---|---| | **CT CAP** | 85–90% | 90% | Standard for pN+ disease | Moderate (CT) | Moderate | | **PET-CT** | 90–95% | 85% | Symptomatic or high-risk disease | High (CT + PET) | High | | **Chest X-ray + LFTs** | 60–70% | 80% | Initial screening (outdated) | Low | Low | | **Bone scan** | 70–80% | 85% | Symptomatic bone pain (outdated) | Moderate | Low | **Mnemonic: CAP for Node-Positive** — CT Abdomen and Pelvis: standard for Axillary node-positive breast cancer, Practical, cost-effective. ### Staging Algorithm for Node-Positive Breast Cancer ```mermaid flowchart TD A[Invasive breast cancer with pN1/pN2/pN3]:::outcome --> B{Symptoms of metastatic disease?}:::decision B -->|No symptoms| C[CT chest, abdomen, pelvis]:::action B -->|Bone pain, neurologic symptoms| D[Add bone scan or PET-CT]:::action C --> E{Metastases detected?}:::decision E -->|No M0| F[Adjuvant chemotherapy + endocrine/targeted therapy]:::action E -->|Yes M1| G[Palliative systemic therapy, clinical trial consideration]:::action D --> H[Complete staging, treatment planning]:::outcome ``` ### When Each Investigation is Used **CT CAP (Standard):** - Node-positive disease (pN1–pN3) - Locally advanced disease (T3–T4) - Asymptomatic staging **PET-CT (Selective):** - High-risk disease (pN3, T4) - Symptoms suggestive of metastases - Equivocal findings on CT - Not routinely recommended for asymptomatic pN1 disease due to cost and radiation **Bone Scan (Outdated):** - Largely replaced by PET-CT - Low specificity (high false-positive rate from benign bone disease) - Reserved for symptomatic bone pain if PET-CT unavailable **Chest X-ray + LFTs (Insufficient):** - Inadequate sensitivity for detecting small metastases - No longer recommended as sole staging modality for node-positive disease - May be used as initial screening in resource-limited settings